Search

Your search keyword '"Andrianarisoa, Meja"' showing total 14 results
Start Over Author "Andrianarisoa, Meja"
14 results on '"Andrianarisoa, Meja"'

1. Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)

Author

Andrianarisoa, Méja, Aouizerate, Bruno, Berna, Fabrice, Blanc, Olivier, Brunel, Lore, Bulzacka, Ewa, Capdevielle, Delphine, Chéreau-Boudet, Isabelle, Chesnoy-Servanin, Gabrielle, Danion, Jean-Marie, D'Amato, Thierry, Deloge, Arnaud, Delorme, Claire, Denizot, Hélène, Dorey, Jean-Michel, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Fluttaz, Cécile, Fond, Guillaume, Fonteneau, Sandrine, Gabayet, Franck, Giraud-Baro, Elisabeth, Hardy-Baylé, Marie-Christine, Lacelle, Delphine, Lançon, Christophe, Laouamri, Hakim, Leboyer, Marion, Le Gloahec, Tifenn, Le Strat, Yann, Llorca, Pierre-Michel, Mallet, Jasmina, Metairie, Emeline, Misdrahi, David, Passerieux, Christine, Peri, Pauline, Pires, Sylvie, Portalier, Céline, Rey, Romain, Roman, Céline, Sebilleau, Mathilde, Schandrin, Aurélie, Schneider, Priscille, Schurhoff, Franck, Tessier, Arnaud, Tronche, Anne-Marie, Urbach, Mathieu, Vaillant, Florence, Vehier, Aurélie, Vidailhet, Pierre, Vilà, Estelle, Yazbek, Hanan, Zinetti-Bertschy, Anna, Godin, Ophelia, Schürhoff, Frank, Boyer, Laurent, Myrtille, Andre, Andrianarisoa, Meja, Chereau, Isabelle, Lancon, Christophe, Leignier, Sylvain, Roux, Paul, and Costagliola, Dominique

Published
2019
Full Text
View/download PDF

2. Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort

Author

Fond, Guillaume, Boyer, Laurent, Andrianarisoa, Meja, Godin, Ophelia, Bulzacka, Ewa, Berna, Fabrice, Brunel, Lore, Coulon, Nathalie, Aouizerate, Bruno, Capdevielle, Delphine, Chereau, Isabelle, D'amato, Thierry, Denizot, Hélène, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Leignier, Sylvain, Mallet, Jasmina, Misdrahi, David, Rey, Romain, Lancon, Christophe, Passerieux, Christine, Schandrin, Aurélie, Urbach, Mathieu, Vidailhet, Pierre, Leboyer, Marion, Schurhoff, Franck, and Llorca, Pierre-Michel

Published
2018
Full Text
View/download PDF

3. Advanced Paternal Age is associated with earlier schizophrenia onset in offspring. Results from the national multicentric FACE-SZ cohort

Author

Fond, Guillaume, Godin, Ophélia, Boyer, Laurent, Llorca, Pierre-Michel, Andrianarisoa, Meja, Brunel, Lore, Aouizerate, Bruno, Berna, Fabrice, Capdevielle, Delphine, D’Amato, Thierry, Denizot, Hélène, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Gabayet, Franck, Mallet, Jasmina, Misdrahi, David, Passerieux, Christine, Rey, Romain, Richieri, Raphaelle, Schandrin, Aurélie, Urbach, Mathieu, vidailhet, Pierre, Leboyer, Marion, Bulzacka, Ewa, and Schürhoff, Franck

Published
2017
Full Text
View/download PDF

4. Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset

Author

Fond, Guillaume, Boyer, Laurent, Boucekine, Mohamed, Aden, Latif A., Schürhoff, Franck, Tessier, Arnaud, Andrianarisoa, Meja, Berna, Fabrice, Brunel, Lore, Capdevielle, Delphine, Chereau, Isabelle, Mallet, Jasmina, Denizot, Hélène, Dorey, Jean Michel, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Gabayet, Franck, Rey, Romain, Richieri, Raphaelle, Passerieux, Christine, Schandrin, Aurélie, Urbach, Mathieu, Vidailhet, Pierre, Llorca, Pierre Michel, and Misdrahi, David

Published
2017
Full Text
View/download PDF

5. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics

Author

Misdrahi, David, Tessier, Arnaud, Daubigney, Antoine, Meissner, Wassilios, Schurhoff, Franck, Boyer, Laurent, Godin, Ophélia, Bulzacka, Ewa, Aouizerate, Bruno, Andrianarisoa, Meja, Berna, Fabrice, Capdevielle, Delphine, Chereau-Boudet, Isabelle, D’amato, Thierry, Dubertret, Caroline, Dubreucq, Julien, Faget-Agius, Catherine, Lançon, Christophe, Mallet, Jasmina, Passerieux, Christine, Rey, Romain, Schandrin, Aurélie, Urbach, Mathieu, Vidailhet, Pierre, Llorca, Pierre, Fond, Guillaume, Fondation FondaMental [Créteil], Université Panthéon-Sorbonne - UFR Histoire (UP1 UFR09), Université Panthéon-Sorbonne (UP1), Université de Bordeaux (UB), Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Hôpital Charles Perrens, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centres d'addictologies - Région Centre, CHU Clermont-Ferrand, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Laboratoire de neuropsychologie cognitive et prise en charge des troubles de la communication schizophrénique, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Hôpital Mignot, Neuropsychiatrie : recherche épidémiologique et clinique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital Civil de Strasbourg, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Université Montpellier 1 - UFR de Médecine (UM1 Médecine), Université Montpellier 1 (UM1), Université Paris 1 Panthéon-Sorbonne - UFR Histoire (UP1 UFR09), Université Paris 1 Panthéon-Sorbonne (UP1), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg-Université de Strasbourg (UNISTRA), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Paris 1 Panthéon-Sorbonne - École d'Histoire (UP1 UFR09), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre hospitalier Charles Perrens [Bordeaux], Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg

Subjects
antipsychotics, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, neurology, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, movement disorders, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, ComputingMilieux_MISCELLANEOUS, schizophrenia/schizoaffective disorders
Abstract

International audience; Background: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing. Objective: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia. Methods: Between 2010 and 2016, patients suffering from schizophrenia (DSM-IV-TR criteria) were recruited through the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) network and data were collected during a comprehensive 1-day-long standardized evaluation. The Simpson-Angus Scale and the Abnormal Involuntary Movement Scale were used to assess drug-induced parkinsonism (DIP) and tardive dyskinesia, respectively. Results: The overall prevalence of DIP and tardive dyskinesia was 13.2% and 8.3%, respectively, in this community-dwelling sample of 674 patients. DIP was associated with negative symptoms (Positive and Negative Syndrome Scale [PANSS] subscore) (adjusted odds ratio [aOR] = 1.102, P Conclusions: Our results indicate the high prevalence of EPS in a nonselected community-dwelling clinically stable sample of outpatients with schizophrenia. In the monitoring of antipsychotic treatment, EPS should be systematically evaluated, especially when negative symptoms and disorganization or cognitive alteration are present. Monotherapy with a second-generation antipsychotic should be preferentially initiated for patients with these side effects.

Published
2019

6. Extrapyramidal side effects of antipsychotics: prevalence and risk factors. Results from the national FACE-SZ cohort Cover title Extrapyramidal side effects and antipsychotics

Author

Misdrahi, David, Tessier, Arnaud, Daubigney, Antoine, Meissner, Wassilios, Schürhoff, Franck, Boyer, Laurent, Godin, Ophelia, Bulzacka, Ewa, Aouizerate, Bruno, Andrianarisoa, Meja, Berna, Fabrice, Capdevielle, Delphine, Chereau-Boudet, Isabelle, D’amato, Thierry, Dubertret, Caroline, Dubreucq, Julien, Faget-Agius, Catherine, Lançon, Christophe, Mallet, Jasmina, Passerieux, Christine, Rey, Romain, Schandrin, Aurélie, Urbach, Mathieu, Vidailhet, Pierre, Llorca, Pierre-Michel, Fond, Guillaume, Fondation FondaMental [Créteil], Université de Bordeaux (UB), Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Pierre Louis Institute of Epidemiology and Public Health, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centres d'addictologies - Région Centre, CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7), Centre Référent de Réhabilitation Psychosociale [CH Alpes Isère], Centre Hospitalier Alpes Isère, Assistance Publique - Hôpitaux de Marseille (APHM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), ANR-11-IDEX-0004,SUPER,Sorbonne Universités à Paris pour l'Enseignement et la Recherche(2011), ANR-10-COHO-0010,Psy-COH,FondaMental-Cohortes(2010), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Assistance Publique-Hôpitaux de Marseille (AP-HM)

Subjects
[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health
Abstract

International audience; Background: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing.Objective: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia.Methods: Between 2010 and 2016, patients suffering from schizophrenia (DSM-IV-TR criteria) were recruited through the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) network and data were collected during a comprehensive 1-day-long standardized evaluation. The Simpson-Angus Scale and the Abnormal Involuntary Movement Scale were used to assess drug-induced parkinsonism (DIP) and tardive dyskinesia, respectively.Results: The overall prevalence of DIP and tardive dyskinesia was 13.2% and 8.3%, respectively, in this community-dwelling sample of 674 patients. DIP was associated with negative symptoms (Positive and Negative Syndrome Scale [PANSS] subscore) (adjusted odds ratio [aOR] = 1.102, P < .001), first-generation antipsychotic prescription (aOR = 2.038, P = .047), and anticholinergic drug administration (aOR = 2.103, P = .017) independently of sex, age, disorganization (PANSS disorganized factor), and antipsychotic polytherapy. Tardive dyskinesia was associated with PANSS disorganized factor (aOR = 1.103, P = .049) independently of sex, age, negative symptoms, excitation, first-generation antipsychotic prescription, and benzodiazepine and anticholinergic drug administration.Conclusions: Our results indicate the high prevalence of EPS in a nonselected community-dwelling clinically stable sample of outpatients with schizophrenia. In the monitoring of antipsychotic treatment, EPS should be systematically evaluated, especially when negative symptoms and disorganization or cognitive alteration are present. Monotherapy with a second-generation antipsychotic should be preferentially initiated for patients with these side effects.

Published
2019

7. Hypovitaminosis D is associated with depression and anxiety in schizophrenia: results from the national FACE-SZ cohort. Running title: hypovitaminosis D, depression and anxiety in schizophrenia

Author

Fond, Guillaume, Godin, Ophelia, Schurhoff, Franck, Berna, F., Bulzacka, Ewa, Andrianarisoa, Meja, Brunel, Lore, Aouizerate, Bruno, Capdevielle, Delphine, Chereau, Isabelle, Coulon, Nathalie, d'Amato, Thierry, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Lancon, Christophe, Leignier, Sylvain, Mallet, Jasmina, Misdrahi, David, Passerieux, Christine, Rey, Romain, Schandrin, Aurélie, Urbach, Mathieu, Vidailhet, Pierre, Leboyer, Marion, Boyer, L., Llorca, Pierre Michel, Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Fondation FondaMental [Créteil], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université de Bordeaux (UB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7), Centre Référent de Réhabilitation Psychosociale [CH Alpes Isère], Centre Hospitalier Alpes Isère, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université de Strasbourg (UNISTRA), ANR-11-IDEX-0004,SUPER,Sorbonne Universités à Paris pour l'Enseignement et la Recherche(2011), ANR-10-COHO-0010,Psy-COH,FondaMental-Cohortes(2010), Université de Lyon, Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), 2011 Programme Hospitalier de Recherche Clinique National and the French Ministry of Health (Direction Générale de la Santé), as well as grants from Janssen Pharmaceutical Companies and the Fondation de France (PHRC-12-024-0278, Afssaps B110684-50, Comité de Protection des Personnes 2011-A00668-33), Assistance Publique-Hôpitaux de Marseille (AP-HM), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre de recherche en neurosciences de Lyon (CRNL)

Subjects
Depression, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Schizophrenia, Vitamin D, Anxiety, Metabolic syndrome
Abstract

International audience; ObjectiveHypovitaminosis D has been associated with respectively major depressive disorder, schizophrenia (SZ) and cognitive disorders in the general population, and with positive and negative symptoms and metabolic syndrome in schizophrenia. The objectives were (i) to determine the prevalence of hypovitaminosis D and associated factors (with a focus on depression and cognition) in a national non-selected multicentric sample of community-dwelling SZ subjects (ii) to determine the rate of SZ patients being administered vitamin D supplementation and associated factors.MethodsA comprehensive 2 daylong clinical and neuropsychological battery was administered in 140 SZ subjects included between 2015 and 2017 in the national FondaMental Expert Center (FACE-SZ) Cohort. Hypovitaminosis D was defined by blood vitamin D level 0.05), however, a trend toward significance has been found for metabolic syndrome (p = 0.06). Vitamin D supplementation has been administered during the previous 12 months in only 8.5% of the subjects but was associated with lower depressive symptoms (aOR = 0.67 [0.46–0.98], p = 0.04) and lower rate of current anxiety disorder (aOR = 0.06 [0.01–0.66], p = 0.02) compared to patients with hypovitaminosis D.ConclusionHypovitaminosis D is frequent and associated with depressive symptoms and anxiety disorders in schizophrenia. Vitamin D supplementation is associated with lower depressive and anxiety symptoms, however patients with hypovitaminosis D remain insufficiently treated.

Published
2018

9. Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia

Author

Godin, Ophelia, Leboyer, Marion, Schürhoff, Frank, Llorca, Pierre-Michel, Boyer, Laurent, Andre, Myrtille, Andrianarisoa, Meja, Aouizerate, Bruno, Berna, Fabrice, Capdevielle, Delphine, Chéreau, Isabelle, Dorey, Jean-Michel, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Lançon, Christophe, Leignier, Sylvain, Mallet, Jasmina, Misdrahi, David, Passerieux, Christine, Rey, Romain, Roux, Paul, Vidailhet, Pierre, Costagliola, Dominique, Fond, Guillaume, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Laboratoire Hubert Curien (LHC), Institut d'Optique Graduate School (IOGS)-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Fondation FondaMental [Créteil], Centre hospitalier Charles Perrens [Bordeaux], Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Service de psychiatrie, CHU Clermont-Ferrand, Psychiatrie, Centre Hospitalier le Vinatier [Bron], Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Laboratoire de sciences cognitives et psycholinguistique (LSCP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), INSERM U955, équipe 15, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire Hubert Curien [Saint Etienne] (LHC), Institut d'Optique Graduate School (IOGS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Charles Perrens, Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS)-Institut d'Optique Graduate School (IOGS), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Pierre et Marie Curie - Paris 6 (UPMC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Pôle de psychiatrie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-CHU Marseille, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), and Assistance Publique-Hôpitaux de Marseille (AP-HM)

Subjects
[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

10. Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)

Author

Godin, Ophelia, primary, Fond, Guillaume, additional, Bulzacka, Ewa, additional, Schürhoff, Frank, additional, Boyer, Laurent, additional, Myrtille, Andre, additional, Andrianarisoa, Meja, additional, Aouizerate, Bruno, additional, Berna, Fabrice, additional, Capdevielle, Delphine, additional, Chereau, Isabelle, additional, Dorey, Jean-Michel, additional, Dubertret, Caroline, additional, Dubreucq, Julien, additional, Faget, Catherine, additional, Lancon, Christophe, additional, Leignier, Sylvain, additional, Mallet, Jasmina, additional, Misdrahi, David, additional, Passerieux, Christine, additional, Rey, Romain, additional, Roux, Paul, additional, Vidailhet, Pierre, additional, Costagliola, Dominique, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Andrianarisoa, Méja, additional, Blanc, Olivier, additional, Brunel, Lore, additional, Chéreau-Boudet, Isabelle, additional, Chesnoy-Servanin, Gabrielle, additional, Danion, Jean-Marie, additional, D'Amato, Thierry, additional, Deloge, Arnaud, additional, Delorme, Claire, additional, Denizot, Hélène, additional, Fluttaz, Cécile, additional, Fonteneau, Sandrine, additional, Gabayet, Franck, additional, Giraud-Baro, Elisabeth, additional, Hardy-Baylé, Marie-Christine, additional, Lacelle, Delphine, additional, Lançon, Christophe, additional, Laouamri, Hakim, additional, Le Gloahec, Tifenn, additional, Le Strat, Yann, additional, Metairie, Emeline, additional, Peri, Pauline, additional, Pires, Sylvie, additional, Portalier, Céline, additional, Roman, Céline, additional, Sebilleau, Mathilde, additional, Schandrin, Aurélie, additional, Schneider, Priscille, additional, Schurhoff, Franck, additional, Tessier, Arnaud, additional, Tronche, Anne-Marie, additional, Urbach, Mathieu, additional, Vaillant, Florence, additional, Vehier, Aurélie, additional, Vilà, Estelle, additional, Yazbek, Hanan, additional, and Zinetti-Bertschy, Anna, additional

Published
2019
Full Text
View/download PDF

11. Chronic Peripheral Inflammation is Associated With Cognitive Impairment ă in Schizophrenia: Results From the Multicentric FACE-SZ Dataset

Author

Bulzacka, Ewa, Boyer, Laurent, Schürhoff, Franck, Godin, Ophélia, Berna, Fabrice, Brunel, Lore, Andrianarisoa, Meja, Aouizerate, Bruno, Capdevielle, Delphine, Chereau-Boudet, Isabelle, Chesnoy-Servanin, Gabrielle, Danion, Jean-Marie, Dubertret, Caroline, Dubreucq, Julien, Faget, Catherine, Gabayet, Franck, Le Gloahec, Tifenn, Llorca, Pierre-Michel, Mallet, Jasmina, Misdrahi, David, Rey, Romain, Richieri, Raphaëlle, Passerieux, Christine, Roux, Paul, Yazbek, Hanan, Leboyer, Marion, Fond, Guillaume, Ctr, FACE-SZ FondaMental Acad, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation FondaMental [Créteil], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Pôle de Psychiatrie et d’Addictologie, Hôpitaux Universitaires Henri-Mondor, Université Pierre et Marie Curie - Paris 6 (UPMC), INSERM Unit 708-Neuroepidemiology, Paris, France, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Hôpital Charles Perrens, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service Universitaire de Psychiatrie Adulte, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital La Colombière, Centres d'addictologies - Région Centre, CHU Clermont-Ferrand, Physiopathologie clinique et expérimentale de la schizophrénie, Université Louis Pasteur - Strasbourg I-IFR37-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire de santé publique évaluation des systèmes de soins et santé perçue, Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Service de psychiatrie adulte - B, Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Unité Académique de Psychiatrie, Centre Hospitalier de Versailles André Mignot (CHV), Laboratoire de sciences cognitives et psycholinguistique (LSCP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Interdisciplinary Institute for Neuroscience (IINS), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), INSERM U955, équipe 15, Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier-Réseau de coopération scientifique en santé mentale, Fondation FondaMental [Créteil]-Fondation FondaMental [Créteil]-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre hospitalier Charles Perrens [Bordeaux], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), École normale supérieure - Paris (ENS-PSL), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL)

Subjects
Adult, Male, medicine.medical_specialty, [SHS.PSY]Humanities and Social Sciences/Psychology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Semantic memory, Humans, Cognitive Dysfunction, Psychiatry, Inflammation, biology, Working memory, C-reactive protein, Cognitive flexibility, Neuropsychology, Cognition, Regular Article, Middle Aged, medicine.disease, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Comorbidity, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, C-Reactive Protein, Schizophrenia, quality, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Chronic Disease, biology.protein, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Psychology, 030217 neurology & neurosurgery
Abstract

International audience; Objectives: Inflammation, measured by abnormal blood C-reactive protein ă (CRP) level, has been described in schizophrenia (SZ), being ă inconsistently related to impaired cognitive functions. The aim of the ă present study is to investigate cognitive impairment associated with ă abnormal CRP levels in a large multi-centric sample of ă community-dwelling SZ patients, using a comprehensive neuropsychological ă battery. Method: Three hundred sixty-nine community-dwelling stable SZ ă subjects (76.2% men, mean age 32.7 y) were included and tested with a ă comprehensive battery of neuropsychological tests. Abnormal CRP level ă was defined as >3 mg/L. Results: Multiple factor analysis revealed that ă abnormal CRP levels, found in 104 patients (28.2%), were associated ă with impaired General Intellectual Ability and Abstract Reasoning (aOR = ă 0.56, 95% CI 0.35-0.90, P = .014), independently of age, sex, education ă level, psychotic symptomatology, treatments, and addiction ă comorbidities. Abnormal CRP levels were also associated with the decline ă of all components of working memory (respectively effect size [ ES] = ă 0.25, P = .033; ES = 0.27, P = .04; ES = 0.33, P = .006; and ES = 0.38, ă P = .004) and a wide range of other impaired cognitive functions, ă including memory (ES = 0.26, P = .026), learning abilities (ES = 0.28, P ă = .035), semantic memory (ES = 0.26, P = .026), mental flexibility (ES = ă 0.26, P = .044), visual attention (ES = 0.23, P = .004) and speed of ă processing (ES = 0.23, P = .043). Conclusion: Our results suggest that ă abnormal CRP level is associated with cognitive impairment in SZ. ă Evaluating the effectiveness of neuroprotective anti-inflammatory ă strategies is needed in order to prevent cognitive impairment in SZ.

Published
2016

12. Efficacy and Safety of Combined Paliperidone Palmitate and Olanzapine Pamoate in Resistant Schizoaffective Disorder

Author

Figorilli, Michela, Ferri, Raffaele, Zibetti, Maurizio, Beudin, Patricia, Puligheddu, Monica, Lopiano, Leonardo, Cicolin, Alessandro, Durif, Frank, marques, ana, Fantini, Maria Livia, Boussida, Salem, Traore, Amidou, Charpier, Stéphane, Legrand, Guillaume, Andrianarisoa, Meja, Mauvieux, Joëlle, Jalenques, Isabelle, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Groupe de sociologie politique et morale (GSPM), École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Qualité des Produits Animaux (QuaPA), Institut National de la Recherche Agronomique (INRA), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Biologie du développement et reproduction (BDR), École nationale vétérinaire d'Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Centre National de la Recherche Scientifique (CNRS), Fondation FondaMental [Créteil], Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Sainte-Marie, Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-CHU Clermont-Ferrand, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS)

Subjects
Paliperidone Palmitate, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Olanzapine pamoate, Schizoaffective disorder, Pharmacology, medicine.disease, 3. Good health, 030227 psychiatry, 03 medical and health sciences, Psychiatry and Mental health, 0302 clinical medicine, Medicine, Pharmacology (medical), business, ComputingMilieux_MISCELLANEOUS, 030217 neurology & neurosurgery
Abstract

International audience

Published
2014

13. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.

Author

Misdrahi D, Tessier A, Daubigney A, Meissner WG, Schurhoff F, Boyer L, Godin O, Bulzacka E, Aouizerate B, Andrianarisoa M, Berna F, Capdevielle D, Chereau-Boudet I, D'Amato T, Dubertret C, Dubreucq J, Faget-Agius C, Lançon C, Mallet J, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Llorca PM, and Fond G

Subjects
Adult, Antipsychotic Agents administration & dosage, Diagnostic and Statistical Manual of Mental Disorders, Female, France epidemiology, Humans, Independent Living statistics & numerical data, Male, Medication Therapy Management standards, Needs Assessment, Prevalence, Psychiatric Status Rating Scales, Risk Factors, Schizophrenia epidemiology, Antipsychotic Agents adverse effects, Dyskinesia, Drug-Induced diagnosis, Dyskinesia, Drug-Induced epidemiology, Dyskinesia, Drug-Induced prevention & control, Parkinson Disease, Secondary chemically induced, Parkinson Disease, Secondary diagnosis, Parkinson Disease, Secondary epidemiology, Parkinson Disease, Secondary prevention & control, Schizophrenia drug therapy, Tardive Dyskinesia chemically induced, Tardive Dyskinesia diagnosis, Tardive Dyskinesia epidemiology, Tardive Dyskinesia prevention & control
Abstract

Background: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing., Objective: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia., Methods: Between 2010 and 2016, patients suffering from schizophrenia (DSM-IV-TR criteria) were recruited through the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) network and data were collected during a comprehensive 1-day-long standardized evaluation. The Simpson-Angus Scale and the Abnormal Involuntary Movement Scale were used to assess drug-induced parkinsonism (DIP) and tardive dyskinesia, respectively., Results: The overall prevalence of DIP and tardive dyskinesia was 13.2% and 8.3%, respectively, in this community-dwelling sample of 674 patients. DIP was associated with negative symptoms (Positive and Negative Syndrome Scale [PANSS] subscore) (adjusted odds ratio [aOR] = 1.102, P < .001), first-generation antipsychotic prescription (aOR = 2.038, P = .047), and anticholinergic drug administration (aOR = 2.103, P = .017) independently of sex, age, disorganization (PANSS disorganized factor), and antipsychotic polytherapy. Tardive dyskinesia was associated with PANSS disorganized factor (aOR = 1.103, P = .049) independently of sex, age, negative symptoms, excitation, first-generation antipsychotic prescription, and benzodiazepine and anticholinergic drug administration., Conclusions: Our results indicate the high prevalence of EPS in a nonselected community-dwelling clinically stable sample of outpatients with schizophrenia. In the monitoring of antipsychotic treatment, EPS should be systematically evaluated, especially when negative symptoms and disorganization or cognitive alteration are present. Monotherapy with a second-generation antipsychotic should be preferentially initiated for patients with these side effects., (© Copyright 2019 Physicians Postgraduate Press, Inc.)

Published
2019
Full Text
View/download PDF

14. Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort.

Author

Godin O, Leboyer M, Schürhoff F, Llorca PM, Boyer L, Andre M, Andrianarisoa M, Aouizerate B, Berna F, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Lancon C, Leignier S, Mallet J, Misdrahi D, Passerieux C, Rey R, Roux P, Vidailhet P, Costagliola D, and Fond G

Subjects
Adult, Antipsychotic Agents therapeutic use, Case-Control Studies, France epidemiology, Humans, Logistic Models, Longitudinal Studies, Medication Adherence, Metabolic Syndrome blood, Recurrence, Risk Factors, Schizophrenia drug therapy, Severity of Illness Index, Young Adult, Metabolic Syndrome complications, Schizophrenia complications
Abstract

Objective: Predicting relapse is a major challenge in schizophrenia from a clinical and medico-economic point of view. During recent decades, major psychiatric disorders have been found to be extensively associated with metabolic disorders, even before the illness onset, with a prevalence estimated to be 35% in this population. However, no study to date has, to our knowledge, explored the potential impact of metabolic syndrome (MetS) on relapse., Methods: From 2010 to 2016, 185 patients (mean age = 32 years) with a DSM-IV-TR diagnosis of schizophrenia were included in the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) cohort and followed up for 1 year. Multivariable logistic regression was performed to estimate the adjusted odds ratio for relapse., Results: Thirty-seven percent of stabilized outpatients with schizophrenia (mean illness duration = 11 years) experienced a relapse at least once during the 1 year of follow-up. MetS strongly predicted relapse at 1 year, independently of illness severity, insight into illness, and treatment characteristics (including medication compliance). Patients with MetS at baseline had a 3 times higher risk (95% CI, 1.1-8.4) of experiencing a new episode of psychosis during the 12 months of follow-up., Conclusions: Further studies should determine if reducing or preventing MetS could help to protect subjects with schizophrenia from relapse., (© Copyright 2018 Physicians Postgraduate Press, Inc.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results